Biogen to present nephrology data at ASN Kidney Week
Biogen says it will present new nephrology portfolio data, including long-term Phase 3 EMPAVELI results, at ASN Kidney Week.
Story updates
11:34:36 AM UTC
SquawkNews
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. NASDAQ:BIIB will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking pl…